{"ticker": {"uuid": "f9b4ca3a-d369-4b92-8ef4-dd9fbd09092d", "symbol": "ARGX", "name": "argenx SE", "exchange": "BRU", "country": "BE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences", "summary": "argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, to Argenx's immunology pipeline. Both companies' boards have approved the deal, which the companies expect to close in the third quarter of 2026. Why Argenx Needs a Second Act argenx SE (NASDAQ:ARGX) has built its business almost entirely around one blockbuster drug, Vyvgart, which treats several autoimm", "url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-favor-argenx-argx-183557286.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T18:35:57+00:00", "published_display": "11 Aug 2026 18:35", "sentiment": "positive", "sentiment_pct": 88, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.305, "duplicate_count": 1, "topics": ["Biotech", "Immunology", "M A"]}, {"title": "argenx (ENXTBR:ARGX) Draws Fresh Valuation Debate, Is The Stock Overvalued Or Undervalued?", "summary": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recent share performance and business profile Without a single clear news event driving headlines, argenx (ENXTBR:ARGX) has still drawn attention after a recent move in its share price and steady gains over the past year. The stock last closed at \u20ac767, with returns around 0.5% over the past day and roughly 6% over the past week. Over the past month the move has been closer to flat, while the past 3 months show a gain of abou", "url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-draws-fresh-161353432.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:13:53+00:00", "published_display": "11 Aug 2026 16:13", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.318, "duplicate_count": 1, "topics": ["Autoimmune Diseases", "Balance Sheet", "Biotech", "Discounted Cash Flow", "Revenue Growth", "Revenue Growth"]}, {"title": "argenx (ENXTBR:ARGX) Stock Looks Fully Valued Despite Strong Returns And Deal Hopes", "summary": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how much optimism is already reflected in the price. argenx has returned 193.8% over the past five years, which puts extra focus on whether recent gains are backed by enduring fundamentals rather than just momentum. The tender offer to acquire Forte Biosciences may support growth expectations if integration goes well. At the sa", "url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-stock-looks-111149889.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T11:11:49+00:00", "published_display": "11 Aug 2026 11:11", "sentiment": "positive", "sentiment_pct": 84, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.249, "duplicate_count": 1, "topics": ["Acquisition", "Biotech", "Earnings", "Share Price"]}, {"title": "argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition", "summary": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. argenx (ENXTBR:ARGX) is set to consider and discuss the acquisition of Forte Biosciences, Inc. The potential deal would expand argenx's reach in biopharmaceutical research and development. Management attention on the proposed acquisition could influence argenx's capital allocation priorities. Investors are watching for details on valuation terms and integration plans once disclosed. This kind of transaction is one part of a broader opportunity set in bioph", "url": "https://finance.yahoo.com/healthcare/articles/argenx-enxtbr-argx-considering-forte-221159692.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T22:11:59+00:00", "published_display": "10 Aug 2026 22:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.237, "duplicate_count": 1, "topics": ["Autoimmune Diseases", "Biotech", "Immunology", "M A", "Share Price"]}], "by_tier": {"direct": [{"title": "Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences", "summary": "argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, to Argenx's immunology pipeline. Both companies' boards have approved the deal, which the companies expect to close in the third quarter of 2026. Why Argenx Needs a Second Act argenx SE (NASDAQ:ARGX) has built its business almost entirely around one blockbuster drug, Vyvgart, which treats several autoimm", "url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-favor-argenx-argx-183557286.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T18:35:57+00:00", "published_display": "11 Aug 2026 18:35", "sentiment": "positive", "sentiment_pct": 88, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.305, "duplicate_count": 1, "topics": ["Biotech", "Immunology", "M A"]}, {"title": "argenx (ENXTBR:ARGX) Draws Fresh Valuation Debate, Is The Stock Overvalued Or Undervalued?", "summary": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recent share performance and business profile Without a single clear news event driving headlines, argenx (ENXTBR:ARGX) has still drawn attention after a recent move in its share price and steady gains over the past year. The stock last closed at \u20ac767, with returns around 0.5% over the past day and roughly 6% over the past week. Over the past month the move has been closer to flat, while the past 3 months show a gain of abou", "url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-draws-fresh-161353432.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T16:13:53+00:00", "published_display": "11 Aug 2026 16:13", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.318, "duplicate_count": 1, "topics": ["Autoimmune Diseases", "Balance Sheet", "Biotech", "Discounted Cash Flow", "Revenue Growth", "Revenue Growth"]}, {"title": "argenx (ENXTBR:ARGX) Stock Looks Fully Valued Despite Strong Returns And Deal Hopes", "summary": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how much optimism is already reflected in the price. argenx has returned 193.8% over the past five years, which puts extra focus on whether recent gains are backed by enduring fundamentals rather than just momentum. The tender offer to acquire Forte Biosciences may support growth expectations if integration goes well. At the sa", "url": "https://finance.yahoo.com/markets/stocks/articles/argenx-enxtbr-argx-stock-looks-111149889.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T11:11:49+00:00", "published_display": "11 Aug 2026 11:11", "sentiment": "positive", "sentiment_pct": 84, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.249, "duplicate_count": 1, "topics": ["Acquisition", "Biotech", "Earnings", "Share Price"]}, {"title": "argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition", "summary": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. argenx (ENXTBR:ARGX) is set to consider and discuss the acquisition of Forte Biosciences, Inc. The potential deal would expand argenx's reach in biopharmaceutical research and development. Management attention on the proposed acquisition could influence argenx's capital allocation priorities. Investors are watching for details on valuation terms and integration plans once disclosed. This kind of transaction is one part of a broader opportunity set in bioph", "url": "https://finance.yahoo.com/healthcare/articles/argenx-enxtbr-argx-considering-forte-221159692.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T22:11:59+00:00", "published_display": "10 Aug 2026 22:11", "sentiment": "positive", "sentiment_pct": 59, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.237, "duplicate_count": 1, "topics": ["Autoimmune Diseases", "Biotech", "Immunology", "M A", "Share Price"]}], "industry": [], "sector": []}, "total_fetched": 4, "total_unique": 4, "total_relevant": 4, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 4, "unique_stories": 4, "duplicates_removed": 0, "relevant_stories": 4, "current_evidence": 4, "direct_evidence": 4, "eodhd_articles": 4, "eodhd": {"configured": true, "status": "healthy", "calls_used": 120, "call_budget": 500, "budget_used_pct": 24.0, "requests_made": 24, "last_success_at": "2026-08-13T02:46:17.035175+00:00", "newest_seen_at": "2026-08-13T02:28:06+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3680, "unmapped_mentions": 1784}, "status": "healthy"}, "sentiment_summary": {"positive": 4, "negative": 0, "neutral": 0, "score": 69, "raw_score": 80, "total": 4, "evidence_count": 4, "effective_articles": 3.94, "direct_story_count": 4, "industry_story_count": 0, "sector_story_count": 0, "story_count": 4, "source_count": 1, "source_concentration": 1.0, "direct_share": 100, "dispersion": 11, "confidence": 67, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-11T18:35:57+00:00", "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 62, "events": [{"event": "earnings", "label": "Earnings", "weight": 1.2, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.2, "count": 2}], "positive_events": 4, "negative_events": 0, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "raw_articles": 4, "unique_stories": 4, "duplicates_removed": 0, "relevant_stories": 4, "current_evidence": 4, "direct_evidence": 4, "eodhd_articles": 4, "eodhd": {"configured": true, "status": "healthy", "calls_used": 120, "call_budget": 500, "budget_used_pct": 24.0, "requests_made": 24, "last_success_at": "2026-08-13T02:46:17.035175+00:00", "newest_seen_at": "2026-08-13T02:28:06+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3680, "unmapped_mentions": 1784}, "status": "healthy"}}, "market_context": {"has_market_context": true, "latest_close": 763.2, "latest_week": "2026-08-07", "one_week_move": 2.4, "four_week_move": -0.1, "twelve_week_move": 10.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.571658, "market_dynamics_buy_signal": false, "relative_strength": -1.157544, "fair_value_gap": 39.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.5455, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+2.4% over one week, -0.1% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "News confirmed by price", "tone": "positive", "classification": "confirmed_positive", "summary": "Constructive news tone is being confirmed by positive weekly price action.", "confidence": 76, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Earnings", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 4}], "tiers": [{"label": "Direct company coverage", "count": 4}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 2}, {"label": "Deals and strategy", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "69/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Evidence confidence", "value": "67/100", "tone": "neutral", "text": "3.94 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "News confirmed by price", "tone": "positive", "text": "Constructive news tone is being confirmed by positive weekly price action."}, {"label": "Primary event", "value": "Earnings", "tone": "positive", "text": "62/100 classification confidence."}, {"label": "Company focus", "value": "4", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "11/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+2.4% over one week, -0.1% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences"}], "updated_at": "2026-08-13T02:57:05.218318+00:00", "detail_intelligence": {"headline": "News confirmed by price", "summary": "Constructive news tone is drawn from 4 fresh independent stories, including 4 company-specific items across 1 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 69, "display": "69", "tone": "positive", "note": "Constructive news tone"}, {"label": "Evidence confidence", "value": 67, "display": "67", "tone": "neutral", "note": "solid confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "4 direct stories"}, {"label": "Evidence agreement", "value": 89, "display": "89", "tone": "positive", "note": "11/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 49, "note": "3.94 effective stories"}, {"label": "Source breadth", "value": 20, "note": "1 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 76, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 89, "note": "cross-story consistency"}, {"label": "Source independence", "value": 0, "note": "lower publisher concentration"}], "freshness": 76, "source_independence": 0, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 0, "score": null, "tone": "neutral", "x": 683.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 0, "score": null, "tone": "neutral", "x": 729.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 0, "score": null, "tone": "neutral", "x": 774.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 1, "score": 59, "tone": "positive", "x": 820.6, "y": 118.6, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-08-11", "label": "11 Aug", "count": 3, "score": 86, "tone": "positive", "x": 866.4, "y": 69.5, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 0, "score": null, "tone": "neutral", "x": 912.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "820.6,118.6 866.4,69.5", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Establishing", "tone": "neutral", "recent_score": 80, "prior_score": null, "delta": null, "recent_count": 4, "prior_count": 0, "volume_delta": 4}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 4, "share": 100}, {"label": "4 to 7 days", "count": 0, "share": 0}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 4, "share": 100, "score": 80, "tone": "positive"}], "event_profile": [{"label": "Earnings", "count": 2, "share": 50, "score": 86, "tone": "positive"}, {"label": "Deals and strategy", "count": 2, "share": 50, "score": 72, "tone": "positive"}], "topics": [{"label": "Biotech", "count": 4, "share": 100}, {"label": "Share Price", "count": 2, "share": 50}, {"label": "Revenue Growth", "count": 2, "share": 50}, {"label": "M A", "count": 2, "share": 50}, {"label": "Immunology", "count": 2, "share": 50}, {"label": "Autoimmune Diseases", "count": 2, "share": 50}, {"label": "Earnings", "count": 1, "share": 25}, {"label": "Discounted Cash Flow", "count": 1, "share": 25}, {"label": "Balance Sheet", "count": 1, "share": 25}, {"label": "Acquisition", "count": 1, "share": 25}], "supporting": [{"label": "Direct evidence", "text": "4 current stories are mapped specifically to ARGX."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 89/100, indicating a comparatively coherent tape."}, {"label": "Price response", "text": "Constructive news tone is being confirmed by positive weekly price action."}], "tempering": [{"label": "Source breadth", "text": "Only 1 publisher currently contribute to the measured read."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences", "summary": "argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, to Argenx's immunology pipeline. Both companies' boards have approved the deal, which the companies expect to close in the third quarter of 2026. Why Argenx Needs a Second Act argenx SE (NASDAQ:ARGX) has built its business almost entirely around one blockbuster drug, Vyvgart, which treats several autoimm", "url": "https://finance.yahoo.com/healthcare/articles/hedge-funds-favor-argenx-argx-183557286.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T18:35:57+00:00", "published_display": "11 Aug 2026 18:35", "sentiment": "positive", "sentiment_pct": 88, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.308, "duplicate_count": 1, "topics": ["Biotech", "Immunology", "M A"]}, "article_count": 4, "updated_at": "2026-08-13T01:45:58.553246+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 129.4, "label": "13 Feb 2026", "close": 708.8, "index": 100.0}, {"x": 77.8, "y": 121.2, "label": "20 Feb 2026", "close": 722.4, "index": 101.9}, {"x": 113.6, "y": 160.4, "label": "27 Feb 2026", "close": 657.4, "index": 92.7}, {"x": 149.5, "y": 181.6, "label": "06 Mar 2026", "close": 622.2, "index": 87.8}, {"x": 185.3, "y": 186.7, "label": "13 Mar 2026", "close": 613.8, "index": 86.6}, {"x": 221.1, "y": 204.2, "label": "20 Mar 2026", "close": 584.8, "index": 82.5}, {"x": 256.9, "y": 190.6, "label": "27 Mar 2026", "close": 607.4, "index": 85.7}, {"x": 292.8, "y": 166.6, "label": "03 Apr 2026", "close": 647.2, "index": 91.3}, {"x": 328.6, "y": 145.6, "label": "10 Apr 2026", "close": 682.0, "index": 96.2}, {"x": 364.4, "y": 124.0, "label": "17 Apr 2026", "close": 717.8, "index": 101.3}, {"x": 400.2, "y": 155.1, "label": "24 Apr 2026", "close": 666.2, "index": 94.0}, {"x": 436.1, "y": 154.0, "label": "01 May 2026", "close": 668.0, "index": 94.2}, {"x": 471.9, "y": 152.3, "label": "08 May 2026", "close": 670.8, "index": 94.6}, {"x": 507.7, "y": 138.8, "label": "15 May 2026", "close": 693.2, "index": 97.8}, {"x": 543.5, "y": 134.1, "label": "22 May 2026", "close": 701.0, "index": 98.9}, {"x": 579.3, "y": 125.3, "label": "29 May 2026", "close": 715.6, "index": 101.0}, {"x": 615.2, "y": 94.9, "label": "05 Jun 2026", "close": 766.0, "index": 108.1}, {"x": 651.0, "y": 84.3, "label": "12 Jun 2026", "close": 783.6, "index": 110.6}, {"x": 686.8, "y": 90.2, "label": "19 Jun 2026", "close": 773.8, "index": 109.2}, {"x": 722.6, "y": 83.8, "label": "26 Jun 2026", "close": 784.4, "index": 110.7}, {"x": 758.5, "y": 55.8, "label": "03 Jul 2026", "close": 830.8, "index": 117.2}, {"x": 794.3, "y": 96.2, "label": "10 Jul 2026", "close": 763.8, "index": 107.8}, {"x": 830.1, "y": 103.3, "label": "17 Jul 2026", "close": 752.0, "index": 106.1}, {"x": 865.9, "y": 71.7, "label": "24 Jul 2026", "close": 804.4, "index": 113.5}, {"x": 901.8, "y": 107.6, "label": "31 Jul 2026", "close": 745.0, "index": 105.1}, {"x": 937.6, "y": 96.6, "label": "07 Aug 2026", "close": 763.2, "index": 107.7}], "sentiment_points": [{"x": 699.6, "y": 117.1, "label": "21 Jun 2026", "score": 57}, {"x": 703.5, "y": 119.0, "label": "22 Jun 2026", "score": 56}, {"x": 704.4, "y": 117.1, "label": "22 Jun 2026", "score": 57}, {"x": 706.7, "y": 117.1, "label": "22 Jun 2026", "score": 57}, {"x": 718.0, "y": 126.3, "label": "25 Jun 2026", "score": 52}, {"x": 724.3, "y": 130.0, "label": "26 Jun 2026", "score": 50}, {"x": 726.7, "y": 131.8, "label": "26 Jun 2026", "score": 49}, {"x": 734.8, "y": 126.3, "label": "28 Jun 2026", "score": 52}, {"x": 755.7, "y": 115.3, "label": "02 Jul 2026", "score": 58}, {"x": 756.2, "y": 115.3, "label": "02 Jul 2026", "score": 58}, {"x": 759.3, "y": 115.3, "label": "03 Jul 2026", "score": 58}, {"x": 759.7, "y": 119.0, "label": "03 Jul 2026", "score": 56}, {"x": 759.8, "y": 115.3, "label": "03 Jul 2026", "score": 58}, {"x": 777.7, "y": 117.1, "label": "06 Jul 2026", "score": 57}, {"x": 784.2, "y": 109.8, "label": "08 Jul 2026", "score": 61}, {"x": 784.4, "y": 109.8, "label": "08 Jul 2026", "score": 61}, {"x": 795.1, "y": 107.9, "label": "10 Jul 2026", "score": 62}, {"x": 800.2, "y": 107.9, "label": "11 Jul 2026", "score": 62}, {"x": 805.8, "y": 111.6, "label": "12 Jul 2026", "score": 60}, {"x": 814.7, "y": 119.0, "label": "13 Jul 2026", "score": 56}, {"x": 816.4, "y": 117.1, "label": "14 Jul 2026", "score": 57}, {"x": 833.6, "y": 115.3, "label": "17 Jul 2026", "score": 58}, {"x": 842.3, "y": 111.6, "label": "19 Jul 2026", "score": 60}, {"x": 842.7, "y": 115.3, "label": "19 Jul 2026", "score": 58}, {"x": 853.2, "y": 115.3, "label": "21 Jul 2026", "score": 58}, {"x": 858.1, "y": 111.6, "label": "22 Jul 2026", "score": 60}, {"x": 859.4, "y": 111.6, "label": "22 Jul 2026", "score": 60}, {"x": 862.1, "y": 109.8, "label": "23 Jul 2026", "score": 61}, {"x": 862.5, "y": 109.8, "label": "23 Jul 2026", "score": 61}, {"x": 883.7, "y": 115.3, "label": "27 Jul 2026", "score": 58}, {"x": 886.3, "y": 124.5, "label": "27 Jul 2026", "score": 53}, {"x": 887.9, "y": 126.3, "label": "28 Jul 2026", "score": 52}, {"x": 891.6, "y": 122.6, "label": "29 Jul 2026", "score": 54}, {"x": 902.2, "y": 117.1, "label": "31 Jul 2026", "score": 57}, {"x": 927.1, "y": 117.1, "label": "04 Aug 2026", "score": 57}, {"x": 927.4, "y": 117.1, "label": "05 Aug 2026", "score": 57}, {"x": 928.6, "y": 117.1, "label": "05 Aug 2026", "score": 57}, {"x": 931.2, "y": 117.1, "label": "05 Aug 2026", "score": 57}, {"x": 958.0, "y": 128.2, "label": "10 Aug 2026", "score": 51}], "price_path": "42.0,129.4 77.8,121.2 113.6,160.4 149.5,181.6 185.3,186.7 221.1,204.2 256.9,190.6 292.8,166.6 328.6,145.6 364.4,124.0 400.2,155.1 436.1,154.0 471.9,152.3 507.7,138.8 543.5,134.1 579.3,125.3 615.2,94.9 651.0,84.3 686.8,90.2 722.6,83.8 758.5,55.8 794.3,96.2 830.1,103.3 865.9,71.7 901.8,107.6 937.6,96.6", "sentiment_path": "699.6,117.1 703.5,119.0 704.4,117.1 706.7,117.1 718.0,126.3 724.3,130.0 726.7,131.8 734.8,126.3 755.7,115.3 756.2,115.3 759.3,115.3 759.7,119.0 759.8,115.3 777.7,117.1 784.2,109.8 784.4,109.8 795.1,107.9 800.2,107.9 805.8,111.6 814.7,119.0 816.4,117.1 833.6,115.3 842.3,111.6 842.7,115.3 853.2,115.3 858.1,111.6 859.4,111.6 862.1,109.8 862.5,109.8 883.7,115.3 886.3,124.5 887.9,126.3 891.6,122.6 902.2,117.1 927.1,117.1 927.4,117.1 928.6,117.1 931.2,117.1 958.0,128.2", "price_change": 7.7, "sentiment_change": -6, "latest_close": 763.2, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}